Aliuska Carmenate, MD
Internal Medicine · Miami, FLNPI 1770883027
Payments from drug & device makers
Across 126 payments — averaging $21.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$886
- Lilly USA, LLC$239
- AstraZeneca$206
- Amgen$179
- Viiv Healthcare Company$177
- Idorsia Pharmaceuticals US Inc$133
- plus $846 from 16 others
What the payments were for
- Food & beverage$2,59197%
- Education$753%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $886 |
| Lilly USA, LLC | 12 | $239 |
| AstraZeneca | 5 | $206 |
| Amgen(2 entities) | 10 | $179 |
| Viiv Healthcare Company | 4 | $177 |
| Idorsia Pharmaceuticals US Inc | 6 | $133 |
| Johnson & Johnson | 3 | $123 |
| Astellas Pharma US Inc | 3 | $114 |
| Pfizer | 4 | $93 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $70 |
| Sumitomo Pharma America, Inc. | 3 | $69 |
| Intuitive Surgical | 1 | $60 |
| Exact Sciences | 2 | $53 |
| Novartis | 2 | $41 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Abbott | 2 | $39 |
| Novo Nordisk | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,666 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $102,752 |
| EliquisApixaban | 62 | $92,343 |
| Repatha SureclickEvolocumab | 69 | $73,398 |
| TrulicityDulaglutide | 36 | $58,565 |
| MyrbetriqMirabegron | 40 | $54,344 |
| JanuviaSitagliptin Phosphate | 28 | $48,808 |
| ProliaDenosumab | 26 | $45,900 |
| XareltoRivaroxaban | 37 | $40,930 |
| FarxigaDapagliflozin Propanediol | 30 | $38,527 |
| JardianceEmpagliflozin | 20 | $36,706 |
| MounjaroTirzepatide | 26 | $32,573 |
| LinzessLinaclotide | 15 | $22,973 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $22,636 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $20,740 |
| GemtesaVibegron | 27 | $19,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $38 | $102,75277 claims |
| PfizerEliquis | $93 | $92,34362 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $239 | $91,13862 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $22 | $72,79054 claims |
| Astellas Pharma US IncMyrbetriq | $114 | $54,34440 claims |
| AstraZenecaFarxiga, Symbicort | $206 | $53,15367 claims |
| AmgenProlia | $179 | $45,90026 claims |
| Johnson & JohnsonXarelto | $123 | $40,93037 claims |
| AbbVieLinzess, Synthroid | $886 | $26,55443 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $69 | $19,32527 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Miami
- Mark KutnerMiami$35.7M
- Mercedes Ponce de LeonMiami$6.8M
- Alejandro de la CruzMiami$6.2M
- Roberto SotolongoMiami$5.8M
- Enrique PelayoMiami$5.4M
- Renato DominguezMiami$5.2M
- Ramses VegaMiami$4.4M
- Dunia Llapur HernandezMiami$4.3M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.